Who pays $2B for $68M in sales?
Shionogi paid $2 billion for a company with $68 million in revenue. ArriVent's Phase 3 lung-cancer trial missed its primary endpoint, and Cullinan filed for…
Read issue ↗Shionogi paid $2 billion for a company with $68 million in revenue. ArriVent's Phase 3 lung-cancer trial missed its primary endpoint, and Cullinan filed for…
Read issue ↗This week: retatrutide posted the strongest Phase 3 weight-loss number ever recorded in diabetes, a dead eye drug beat Eylea twice in one trial, Roche killed…
Read issue ↗This week: the FDA approved the first gene therapy for a fatal childhood brain disease, a one-time eye gene therapy posted the first pivotal win ever in XLRP…
Read issue ↗1. Enhertu takes first line in HER2-mutant lung cancer. DESTINY-Lung04 is the first Phase 3 to beat the global first-line standard in HER2-mutant NSCLC. Enhertu…
Read issue ↗Welcome to the first issue of The Compound. I've been wanting to write this for a while — biotech moves too fast for the general press and, honestly, too slow…
Read issue ↗